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Model
• An economic model was developed to examine the impact of switching from SOC to AOM on psychiatric hospitalization rates and associated inpatient and treatment costs among patients with at least 1 hospitalization during the retrospective period (Figure 2) 
Inputs
• Clinical and cost (drug therapy and hospitalization) inputs are presented in Table 1 -Data on psychiatric hospitalizations (percent of patients and number of hospitalizations) were obtained from the clinical trial; for the prospective phase, adjustments were made to estimate additional resource use for patients who discontinued the study and thus did not have complete data on resource use from the trial (Figure 2) • The treatment of schizophrenia causes a significant economic burden to society and healthcare plans -The high cost of treating schizophrenia, estimated to be US$22.7 billion in 2002 and projected to be US$46.7 billion in 2012 when adjusted for inflation using the US Consumer Price Index Medical Care Category, 
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• In this study design -Because there was no parallel control group, it cannot be determined if other treatments may have had a similar effect -It can be difficult to separate drug treatment effects from trial effects -Results may be influenced by independent factors, including admission patterns, insurance coverage, hospital bed availability, and community support -Because the study was not blinded, its influence on the clinical decision to hospitalize or not to hospitalize any given patient cannot be determined • This analysis evaluated only 2 aspects of the cost of care for patients with schizophrenia: antipsychotic medication and hospitalization. However, these are large drivers of economic impact • This analysis only included patients with previous psychiatric hospitalizations; therefore, the cost-saving results may be applicable only to a high-risk schizophrenia patient population Limitations Cost_hosp, hospitalization cost; Cost_medR, average cost of medications per patient for R 6 months; Cost_medPon, average cost of AOM per patient while on P AOM for X months; Cost_medPoff[Cost_medR × (6 -X months)], cost of medication after P AOM discontinuation; Hosp_, hospitalizations; Hosp_days, hospitalization days; Hosp_Pon, patient hospitalization rate while on P AOM; Hosp_Poff, patient hospitalization rate after AOM discontinuation; Hosp_daysPon, hospitalization days while on P AOM; Hosp_daysPoff, hospitalization days after P AOM discontinuation.
AOM, aripiprazole once-monthly; LOS, length of stay; P, prospective; R, retrospective; SOC, standard of care. • Among patients with schizophrenia having at least 1 previous psychiatric hospitalization, treatment initiation with AOM may present cost-saving opportunities for health plans as well as improve patient outcomes by reducing the rate of psychiatric hospitalizations
Conclusions
• The objective of this study was to develop an economic model to estimate healthcare cost savings associated with AOM treatment initiation among patients with at least 1 psychiatric hospitalization prior to initiating treatment with AOM
Study Objective

Patient Population
• From the AOM Mirror study analysis, 11 which investigated psychiatric hospitalization rates among patients switching from oral SOC to AOM, a subgroup of 76 patients with schizophrenia who had at least 1 psychiatric hospitalization during the retrospective period was analyzed (Figure 1) Retrospective Prospective
Methods
Change in Hospitalizations
Hospital days
14.34
6.58
AOM, aripiprazole once-monthly; SOC, standard of care.
